



Press Release

Oncobit announces partnership with Immunocore to advance therapy response analysis in clinical trials.

Zurich, 26.02.2024 - Oncobit, a MedTech spin-off from the University of Zurich developing cancer monitoring tests, is thrilled to announce that it has signed a service agreement with Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. This collaboration aims to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable and real time therapy response marker in clinical trials.

Oncobit's innovative digital PCR platform will be employed to perform ctDNA analysis on clinical samples. The initial phase of this partnership aims to validate the Oncobit™ PM platform's efficacy and establish the tests as a tool for quantifying therapy response in clinical trials. By incorporating Oncobit's ctDNA analysis into Immunocore's clinical trials, the partnership aims to refine the assessment of therapy response.

Dr. Claudia Scheckel, CEO of Oncobit, expressed enthusiasm about the partnership: "We are excited to collaborate with Immunocore, a company that shares our vision for innovation in pioneering cancer care. By contributing to such studies, we are proud to work towards our goal of improving patient outcomes with high-precision and cutting-edge cancer monitoring solutions."

About Oncobit

Oncobit is a Medtech spin-off from the University Hospital of Zurich and has developed a scalable and data-driven cancer monitoring platform based on a unique combination of proprietary digital PCR assays and software. By quantifying specific cancer markers in liquid biopsy, Oncobit aims to optimize therapy management and transform cancer care in a cost and time efficient manner. Oncobit has obtained regulatory approval for its first product focused on melanoma in Europe.

Web links:

<https://oncobit.com>

Contact:

Oncobit AG
Dr. Björn Biedermann, CBO, Oncobit
bjoern.biedermann@oncobit.com
+41 78 256 99 56